Aerie Pharmaceuticals Inc.

Aerie Pharmaceuticals — Technical Presentation (November 2019)

9 slides from Aerie Pharmaceuticals's technical presentation, Nov 6, 2019

  1. Slide 1: Topline Results from Rhopressa Phase 4 Multi-center Open-label Study (MOST)

    Topline Results from Rhopressa (netarsudil ophthalmic solution) 0.02% Phase 4 Multi-center Open-label Study (MOST) November 6, 2019 For Investor Use Exhibit 99.1

  2. Slide 2: Important Information

    Important Information For Investor Use The information in this presentation is current only as of its date and may have changed or may change in the future. We are not making any representation or warranty that the information in this presentation is accurate or complete. Certain statements in this

  3. Slide 3: Efficacy Summary for MOST Study

    Efficacy Summary for MOST Study 12-week MOST study evaluated efficacy, tolerability and safety of Rhopressa use in 260 patients in a real-world clinical setting Use of Rhopressa as monotherapy or adjunct was at discretion of the physician Used adjunctively (n=151, mITT): Rhopressa was similarly effe

  4. Slide 4: Rhopressa Multi-center Open-label Study (MOST)

    Rhopressa Multi-center Open-label Study (MOST) 12-week, prospective, multi-center, non-comparative, open-label 260 subjects diagnosed with open-angle glaucoma (OAG) or ocular hypertension (OHT) Primary Endpoint: Percent change from baseline (BL) in mean IOP at Week 12 Secondary Endpoints: Change fro

  5. Slide 5: Rhopressa Added to Previous Therapy

    Rhopressa Added to Previous Therapy Rhopressa provided consistent IOP reductions whether added to prior PGA monotherapy (-4.3 mmHg) or prior combination therapy (-4.5 mmHg) Adjunct Therapy Treatment Group Baseline Week 6 Week 12 Rhopressa + PGA (n=55) Mean IOP (mmHg) 21.1 17.0 16.9 Δ from BL (mmHg)

  6. Slide 6: Subjects On PGA Monotherapy Switched to Rhopressa Monotherapy

    Subjects On PGA Monotherapy Switched to Rhopressa Monotherapy Monotherapy Treatment Group Baseline Week 6 Week 12 PGA Switched to Rhopressa (n=57) Mean IOP (mmHg) 18.2 17.4 17.5 Δ from BL (mmHg) -- -0.8 (-3.2%) -0.6 (-2.5%) Switch to Rhopressa monotherapy provided similar efficacy to prior PGA monot

  7. Slide 7: Adverse Events

    Adverse Events DC: Discontinuation Adverse Events Rhopressa as Monotherapy N=99 Rhopressa as Adjunct N= 161 Adverse Events (≥ 5%) Conjunctival hyperemia 22 (22.2%) 32 (19.9%) Vision blurred 9 (9.1%) 10 (6.2%) Conjunctival hemorrhage 6 (6.1%) 8 (5.0%) Instillation site pain 6 (6.1%) 8 (5.0%) Adverse

  8. Slide 8: Patient Reported Tolerance

    Patient Reported Tolerance (WK 12 or exit visit) Overall N= 238 Previously Treatment Naïve N=24 Rhopressa Switches N= 66 Adjunct Therapy N=148 Very well 45.0% 50.0% 37.9% 47.3% Mostly well 23.9% 16.7% 28.8% 23.0% Well 20.2% 25.0% 22.7% 18.2% Very Little 8.0% 4.2% 10.6% 7.4% Not able to tolerate 2.9%

  9. Slide 9: Summary for MOST Study

    Summary for MOST Study 12-week MOST study evaluated Rhopressa use in 260 patients in a real world clinical setting Used adjunctively (n=151, mITT): Rhopressa was similarly effective when added to prior PGA monotherapy or when added to prior multi-drug therapy Used as monotherapy (n=91, mITT): Rhopre

Aerie Pharmaceuticals — Technical Presentation (November 2019) on 6ix